SOURCE BioDelivery Sciences International, Inc.
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
We answer recent reader questions about three of the biotech stocks we regularly cover.
This biopharma company's Relistor drug should send revenues sharply higher this year.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.